These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23710937)

  • 1. A note on statistical power in multi-site randomized trials with multiple treatments at each site.
    Liu XS
    Br J Math Stat Psychol; 2014 May; 67(2):231-47. PubMed ID: 23710937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating clinical significance: incorporating robust statistics with normative comparison tests.
    van Wieringen K; Cribbie RA
    Br J Math Stat Psychol; 2014 May; 67(2):213-30. PubMed ID: 23751017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A priori power analysis in longitudinal three-level multilevel models: an example with therapist effects.
    de Jong K; Moerbeek M; van der Leeden R
    Psychother Res; 2010 May; 20(3):273-84. PubMed ID: 19946814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes.
    Austin PC
    Stat Med; 2007 Aug; 26(19):3550-65. PubMed ID: 17238238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing for qualitative interaction using ratios of treatment differences.
    Kitsche A; Hothorn LA
    Stat Med; 2014 Apr; 33(9):1477-89. PubMed ID: 24302387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical power in three-arm cluster randomized trials.
    Liu XS
    Eval Health Prof; 2014 Dec; 37(4):470-87. PubMed ID: 23908381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial: myths around elementary statistical principles.
    Edler L; Kopp-Schneider A
    Onkologie; 2003 Dec; 26(6):551-6. PubMed ID: 14709929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical power and optimal design for multisite randomized trials.
    Raudenbush SW; Liu X
    Psychol Methods; 2000 Jun; 5(2):199-213. PubMed ID: 10937329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Power analysis on the time effect for the longitudinal Rasch model.
    Feddag ML; Blanchin M; Hardouin JB; Sebille V
    J Appl Meas; 2014; 15(3):292-301. PubMed ID: 24992252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the global statistical test and composite outcome for secondary analyses of multiple coronary heart disease outcomes.
    Baraniuk S; Seay R; Sinha AK; Piller LB
    Prog Cardiovasc Dis; 2012; 54(4):357-61. PubMed ID: 22226004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased statistical power with combined independent randomization tests used with multiple-baseline design.
    Tyrrell PN; Corey PN; Feldman BM; Silverman ED
    J Clin Epidemiol; 2013 Jun; 66(6):691-4. PubMed ID: 23466016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of multi-outcome longitudinal studies.
    Jensen SM; Pipper CB; Ritz C
    Stat Med; 2015 May; 34(12):1993-2003. PubMed ID: 25720498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generalized F test and generalized deviance test in two-way ANOVA models for randomized trials.
    Shen J; He X
    J Biopharm Stat; 2014; 24(3):523-34. PubMed ID: 24697334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The analysis of continuous outcomes in multi-centre trials with small centre sizes.
    Pickering RM; Weatherall M
    Stat Med; 2007 Dec; 26(30):5445-56. PubMed ID: 17924360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of rank-based procedures for multicenter clinical trials.
    Rashid MM; McKean JW; Kloke JD
    J Biopharm Stat; 2013; 23(6):1207-27. PubMed ID: 24138428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
    Sullivan LM; D'Agostino RB
    Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A method for testing group differences of scale validity in multiple population studies.
    Raykov T
    Br J Math Stat Psychol; 2005 May; 58(Pt 1):173-84. PubMed ID: 15969845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods for exploring treatment effect heterogeneity in subgroup analysis: an application to global clinical trials.
    Schou IM; C Marschner I
    Pharm Stat; 2015; 14(1):44-55. PubMed ID: 25376518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of bootstrap methods for analysing Health-Related Quality of Life outcomes (particularly the SF-36).
    Walters SJ; Campbell MJ
    Health Qual Life Outcomes; 2004 Dec; 2():70. PubMed ID: 15588308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.